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The safety, pharmacokinetics, and biological effect of plerixafor in children as part of a conditioning regimen
for chemo-sensitization in allogeneic hematopoietic stem cell transplantation (HSCT) have not been studied.
This is a phase I study of plerixafor designed to evaluate its tolerability at dose of .24 mg/kg given intrave-
nously on day 4 (level 1); day 4 and day 3 (level 2); or day 4, day 3, and day 2 (level 3) in com-
bination with ﬂudarabine, thiotepa, melphalan, and rabbit antithymocytic globulin for a second allogeneic
HSCT in children with refractory or relapsed leukemia. Immunophenotype analysis was performed on blood
and bone marrow before and after plerixafor administration. Twelve patients were enrolled. Plerixafor at all
3 levels was well tolerated without dose-limiting toxicity. Transient gastrointestinal side effects of National
Cancer Instituteegrade 1 or 2 in severity were the most common adverse events. The area under the
concentration-time curve increased proportionally to the dose level. Plerixafor clearance was higher in males
and increased linearly with body weight and glomerular ﬁltration rate. The clearance decreased and the
elimination half-life increased signiﬁcantly from dose level 1 to 3 (P < .001). Biologically, the proportion of
CXCR4þ blasts and lymphocytes both in the bone marrow and peripheral blood increased after plerixafor
administration.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The outcome in children with relapsed leukemia under-
going a second allogeneic hematopoietic stem cell trans-
plantation (HSCT) is poor, with a 5-year overall survival
ranging from 30% [1-3] to 48% [4]. Children may experience
lower regimen-related toxicity from a second transplantation
compared with adults [2,4]; however, recurrent disease re-
mains a predominant cause of death. Thus, novel therapeutic
strategies are needed to overcome leukemia resistance to
improve the outcome after second HSCT. Interaction between
leukemia cells and the bone marrow stromal environment is
postulated to be an importantmediator of this resistance [5,6].
The chemokine receptor CXCR4 is expressed in acute myeloid
leukemia (AML) [7] and acute lymphoblastic leukemia [8],edgments on page 1228.
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14.04.020binds to CXCL12 expressed by the marrow stroma, and pro-
motes survival of the leukemic cells. Increased expression of
CXCR4 has been associated with an increased risk of relapse
and poor outcome in acute lymphoblastic leukemia [9], and
AML [10,11].
Plerixafor (Mozobil, Sanoﬁ USA, Bridgewater, NJ) is a
reversible inhibitor of the binding of CXCL12 to CXCR4. It is
FDA approved for use in combination with granulocyte
colonyestimulating factor to mobilize hematopoietic stem
cells in patients with non-Hodgkin’s lymphoma andmultiple
myeloma undergoing autologous transplantation [12,13]. In a
murine model of AML, mice treated with chemotherapy plus
plerixafor had lower tumor burdens and improved overall
survival compared with mice treated with chemotherapy
alone [14]. A phase I/II study of plerixafor in adults with
relapsed or refractory AML showed that the drug was well
tolerated and disrupted the CXCR4/CXCL12 axis [15].
The toxicity, pharmacokinetics, and biological effect of
plerixafor when used in children as part of conditioning for
an allogeneic HSCT is not known. We conducted a phase I
trial to investigate the maximum tolerated dose of plerixafor,
pharmacokinetics, and cell surface expression of CXCR4.Transplantation.
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Study Population
The study was conducted at St. Jude Children’s Research Hospital in
Memphis, Tennessee, and was approved by the hospital’s institutional re-
view board. Consent was obtained from all parents and/or guardians, and
assent was obtained from all children older than 7 years of age.
Eligibility criteria included age  21 years, a hematologic malignancy
that had relapsed after prior allogeneic HSCT, and a scheduled bone marrow
stem cell graft from a 7/8 or 8/8 HLA alleleematched related or unrelated
donor. Patients needed adequate renal, hepatic, cardiac, and pulmonary
function as determined by institutional guidelines. Exclusion criteria
included active central nervous system malignancy, neuromuscular
dysfunction, or ongoing treatment for acute or chronic graft-versus-host
disease (GVHD). All patients had a performance score of 100.
Conditioning regimen included ﬂudarabine 30 mg/m2 on day 9
through day 5, thiotepa 5 mg/kg/dose for 2 doses on day 4, melphalan
70 mg/m2 on day 3 and 2, and rabbit antithymocytic globulin (rATG)
3 mg/kg/day on days 3 through 1 after a test dose of 1 mg/kg on day 4.
GVHD prophylaxis included tacrolimus starting day 2, sirolimus starting
day 0, andmethotrexate 5mg/m2 on daysþ1,þ3, andþ6. Patients at risk for
cytomegalovirus or herpes simplex reactivation received prophylaxis with
acyclovir, and all patients received prophylaxis with metronidazole, co-
trimoxazole, and antifungals in accordance with institutional guidelines.
Plerixafor Dose Schedule
Plerixafor .24mg/kg/daywas given intravenously at 3 dose levels (1 dose,
day 4; level 1), (2 doses, days 4 and 3; level 2), (3 doses, days 4, 3
and 2; level 3). Plerixafor was administered 5 hours before chemotherapy
at each dose level.
Pharmacokinetic Testing
Blood samples for pharmacokinetic testing were obtained before pler-
ixafor and 30minutes and 1, 2, 6,12, and 24 hours after infusion of each dose.
Samples were spun and serawere cryopreserved, batched, and run at a later
date. Samples prepared by a protein precipitation extraction procedure in
sodium heparin plasma were analyzed by liquid chromatography/tandem
mass spectrometry over the concentration range of 5 to 1000 ng/mL. The API
5000 (AB SCIEX, Framingham, MA) was operated in the Multiple Reaction
Monitoringmode under optimized conditions for detection of plerixafor and
AMD16617þ ions formed by electrospray ionization. Calibration standards
were placed at the beginning and end of each bio-analytical run.
Pharmacokinetic Analysis
The population pharmacokinetic and individual post hoc estimates were
determined using nonlinearmixed effects modeling performedwithMonolix
(version 4.2.2, www.monolix.org). A 2-compartment pharmacokinetic model
withﬁrst-order eliminationwasﬁt to thedata. Parameters estimated included
systemic clearance (L/hour or L/hour/kg), volume of distribution (L/kg),
intercompartmental clearance (L/hour, or L/hour/kg), and volume of periph-
eral compartment (mL, or L/kg). The interindividual variability of the pa-
rameterswas assumed to be log normally distributed. A proportional residual
error model was used with assumed normal distribution of the residuals.
Estimates of areaunder the concentration-timecurve from0 to72hours (AUC,
ng  hour/mL), maximum concentration (ng/mL), and minimum concentra-
tion (ng/mL) were determined using the individual post hoc estimates.
Covariates, including demographics, glomerular ﬁltration rate (GFR) as
assessed by Tc99m renal clearance, serum creatinine, aspartate trans-
aminase, alanine transaminase, bilirubin, and absolute neutrophil count
were evaluated to determine their signiﬁcance in explaining pharmacoki-
netic variability. These covariates were considered signiﬁcant in a univariate
analysis if their addition to the model reduced the objective function value
at least 3.84 units (P < .05, based on the chi-square test for the difference in
the 2-log likelihood between 2 hierarchical models that differ by 1 degree of
freedom), and the covariate term was signiﬁcantly different than 0 (P < .05,
t-test).
Immunophenotype Analysis
Blood samples and bone marrow aspirate for immunophenotype anal-
ysis were obtained before plerixafor administration on day 5 and after its
administration on day 4 (before thiotepa administration). The cell content
was phenotyped by ﬂow cytometry using BD FACSCanto II ﬂow cytometer
(BD Biosciences, San Jose, CA), BD FACSDiva 6.0 software (BD Biosciences,
San Jose, CA), and a red cell lysis/multicolor antibody protocol. The following
monoclonal antibodies against cell surface or intracellular markers were
used: Anti-CD45 APC-H7 (Clone 2D1), Anti-CD33 PE-Cy7 (Clone P67.6), Anti-
sCD3 V450 (Clone UCHT1), Anti-CD7 FITC (Clone M-T701), Anti-CD5 PE-Cy7
(Clone L17F12), Anti-CD19 APC (Clone SJ25C1), Anti-CD33 APC (Clone P67.6),
Anti-HLADR APC-H7 (Clone L243), Anti-CD184 (CXCR4) PE (Clone ID9), Anti-IgG 2a PE (Clone X-39; all from BD Biosciences, San Jose, CA); Anti-CD34
PerCP (Clone 581), Anti-cCD3 PerCP (Clone SK7; all from Biolegend, San
Diego, CA); Anti-CD38 FITC (Clone T16; Beckman Coulter, Pasadena, CA) and
Anti-CD133 APC (Clone AC133, Miltenyi Biotec, Cambridge, MA). Patient-
speciﬁc combinations of 6 or 8 antibodies and Boolean gating scheme
were used to identify the blasts for each patient and determine their CXCR4
expression. Matched isotype control was used to determine the upper limit
of ﬂuorescent background.
Toxicity
Dose-limiting toxicity (DLT) was deﬁned as any grade IV organ toxicity
not due to conditioning or underlying malignancy, attributable to plerixafor
from the ﬁrst dose on day4 through dayþ7 after HSCT. Adverse events and
toxicities due to plerixafor were assessed using the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events, version 4.0.
Routine Evaluation
GVHD was assessed in accordance with published criteria [16]. Daily
physical examination and blood testing, including complete blood count and
serum chemistries, were obtained. The day of engraftment was deﬁned as
the ﬁrst of 3 measurements on consecutive days of achieving an absolute
neutrophil count > 500 cells/mL. Primary graft failure was deﬁned as an
absolute neutrophil count never meeting or exceeding 500 cells/mL for 3
measurements on consecutive days by day þ30 after transplantation.
Statistical Design
The maximum tolerated dose was determined using a conventional
phase I study design with cohorts of 3 to 6 patients each. The maximum
tolerated dose was deﬁned as the dose level immediately below the level at
which 2 ormore patients out of a cohort of 3 to 6 patients experienced a DLT.
If no patient experienced a DLTat dose level 1 and 2, then a total of 6 patients
were treated at level 3.
Patients were enrolled in the study between August 2010 and December
2012. All patients received the doses of plerixafor as scheduled. No patient
was lost to follow up. The characteristics of patients are summarized using
frequencies for categorical variables and mean, median, and range for
continuous variables. SAS version 9.2 (SAS Institute, Cary, NC) was used for
statistical analysis.
RESULTS
A total of 12 patients were enrolled in the study. Patient
characteristics are outlined in Table 1. Of the 12 patients, 8
were in complete remission (CR) and 4were inmorphological
relapse at the time of the second transplantation. One of them
had blasts in the peripheral blood. Five patients received total
body irradiationebased conditioning for the ﬁrst trans-
plantation. The median interval between the ﬁrst and the
second transplantationwas11 (range, 3 to24)months. For the
second transplantation, 10 donors were matched unrelated
and 2 were matched siblings. Two patients did not engraft
before they died, both on day þ14, because of infection. For
the remaining 10 patients, the mean time to neutrophil and
platelet engraftment was 22 (range, 13 to 27) days and 34
(range, 17 to 64) days, respectively. The mean time to
neutrophil and platelet engraftment for 10 historical controls
at our center with the same conditioning regimen without
plerixafor, during the same period was 19 (range, 14 to 23)
days and 22 (range, 14 to 42) days, respectively. Criteria for
primary graft failure was not met in this phase I trial. There
were no effects of plerixafor administration on chimerism,
which was full in both lymphoid and myeloid compartments
after transplantation. Themean CD34þ cell dosewas 7.6106
(range, 2.2 to 25.6  106) cells/kg. Grade II to IV GVHD was
seen in 3 patients and no patient had chronic GVHD.
With a mean duration of follow-up of 332 (range, 14 to
754) days, 4 of the 12 patients (33%) are surviving at the time
of this report, 2 (17%) without progression of disease. One of
these patients was on dose level 2 and the other on dose level
3. All 4 patients were in CR before transplantation. Four pa-
tients died of progression of underlying disease on day þ754
(dose level 1), dayþ295 (dose level 1), dayþ94 (dose level 2),
Table 1
Patient Characteristics
Characteristic n
Age, median (range), yr 9 (6-15)
Male sex 8
Diagnosis
AML 8
ALL 4
CR2 4
CR3 4
Bone marrow blasts
5%-25% 2
>90% 2
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CR, complete remission.
N of entire cohort ¼ 12.
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infection: 1 each due to parainﬂuenzavirus type 3 on dayþ14
(dose level 1), disseminated Fusarium oxysporum on day þ14
(dose level 3), and Epstein-Barr viruseinduced lymphopro-
liferative disease on dayþ100 (dose level 3). One patient died
of pleomorphic sarcoma of the chest wall as a second malig-
nancy on day þ129 (dose level 3). There were 2 patients who
relapsed on dayþ260 (dose level 3) and dayþ134 (dose level
3), but both are currently in CR after further chemotherapy
and a third allogeneic HSCT, respectively.Toxicity
Plerixafor at all 3 levels was well tolerated, with none of
the 12 patients experiencing a DLT. Of the 12 patients, 7 had
at least 1 adverse event possibly related to the drug, of NCI
grade 1 (4 patients) or 2 (3 patients) in severity. Nausea and
abdominal pain were the most common adverse events seen
in 3 patients each; observed between day 4 to day 1. One
patient was on dose level 2 and the others on dose level 3.
The abdominal pain resolved in 1 to 3 days, whereas nausea
lasted for 2 days in 1 patient and up 4 to 6 weeks in the other
2 patients. One patient on dose level 1 complained of
headache, NCI grade 2 in severity, and another patient on
dose level 3 had diarrhea, NCI grade 1 in severity, both on
day 1, which resolved in 2 days. No patient experienced a
severe adverse event related to plerixafor.
Of the 12 patients on study, 9 had severe adverse event
unrelated to the use of plerixafor. Three patients had fever
with neutropenia, 1 patient on dose level 1 had veno-
occlusive disease on day þ8, 1 had pericardial effusion
related to Epstein-Barr viruseinduced lymphoproliferative
disease on day þ54, 1 had a sympathetic pericardial/pleural
effusion from a second malignancy on day þ78, 1 had a
pleural effusion related to relapsed leukemia on day þ58,
and 2 patients, who had respiratory failure due to para-
inﬂuenza virus and disseminated Fusarium respectively,
succumbed to the infection.Table 2
Summary Pharmacokinetics of Plerixafor at the Three Dose Levels
Dose Level n Clearance (L/hr/kg) AUC0-24 (ng  hr/mL)
1 3 .15 (.08-0.17) 1480 (1477-3009)
2 3 .10 (.08-.15) 4593 (3333-6058)
3 6 .07 (.04-.09) 9628 (8366-18083)
AUC0-24 indicates area under the concentration-time curve; Cmax, maximum conce
The results are the post hoc median (range) of each variable.
Plerixafor .24 mg/kg/day was given intravenously at 3 dose levels (1 dose; day 4
level 3).Pharmacokinetic Proﬁle
The pharmacokinetics of plerixafor, stratiﬁed by dose
level, are summarized in Table 2. The highest dose cohort
reached a median peak concentration of 801 (range, 693 to
860) ng/mL (Table 2). Plerixafor clearance increased linearly
with bodyweight (P< .01) (Figure1). The clearance decreased
(.15, .10, .07 L/hour/kg for dose level 1, 2, and 3, respectively),
and the elimination half-life increased (2.19, 2.42, 2.77 hours
for dose level 1, 2, and 3, respectively) as the dose escalated
from level 1 to 3 (P < .001) (Table 2). The inclusion of this
change in clearance, relative to the dose level, decreased the
interindividual variability coefﬁcient of variation of clearance
from17.4% to 8.5%. The exposure or AUC to plerixafor over the
ﬁrst 24 hours accounted for 95%, 49%, and 33% of its total
exposure, at dose level 1, 2, and 3, respectively. In addition,we
observed that the weight-normalized clearance of plerixafor
was 50% higher in males (P< .05) and increased with the GFR
(P < .01) (Figure 2). The sole patient with mild renal impair-
ment and a GFR of 67mL/minute/1.73m2 at dose level 3 had a
plerixafor clearance of .04 L/hour/kg, approximately 57%
lower than the median clearance for that cohort. No adverse
events related to plerixafor were observed in this patient.
Clearance was not affected by age.CXCR4 Expression on Leukemic Cells and Lymphocytes
Increases in the percentage of CXCR4þ blasts and lym-
phocytes were documented in both the bone marrow (2
patients) and peripheral blood (3 patients) by ﬂow cytom-
etry after treatment with plerixafor (Figure 3). Of the 2 pa-
tients with adequate marrow samples, bone marrow blasts
remained unchanged with 90% blasts before and after pler-
ixafor in the ﬁrst patient and decreased from 24% to 18% after
plerixafor in the second patient, both on dose level 1. Pe-
ripheral blood blasts were not detected by morphologic re-
view in the ﬁrst patient, decreased from 10% to <1% after
plerixafor in the second patient, and was not detected in the
third patient on dose level 2. Lymphocytes in the peripheral
blood were scant by morphologic review before and after
plerixafor in all 3 patients. The increased proportion of
CXCR4þ blasts detected by ﬂow cytometry did not result in
more leukemia blasts, as detected by bone marrow
morphology in the 2 patients or in the peripheral blood in 3
patients.
The third patient who was in CR2 did not have a satis-
factory bone marrow sample for CXCR4 analysis. Two other
patients with morphological disease before transplantation
(90% and 6% blasts in bonemarrow)were not able to undergo
bone marrow tests before and after plerixafor because of
unstable respiratory status.DISCUSSION
Plerixafor given intravenously for 3 consecutive days at a
dose of .24 mg/kg/day with ﬂudarabine, thiotepa, melphalan,Cmax (ng/mL) Cmin (ng/mL) Half-life (hr)
548 (429-63) 3.80 (1.31-8.84) 2.19 (1.68-3.07)
641 (526-710) 3.96 (3.06-7.25) 2.42 (2.10-2.86)
801 (693-860) 7.15 (1.29-56.38) 2.77 (2.19-6.44)
ntration; Cmin, minimum concentration.
; level 1), (2 doses; days 4 and 3; level 2), (3 doses; days 4, 3 and 2;
Figure 1. Clearance of plerixafor (L/hour) with respect to body weight (kg).
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allogeneic HSCT for recurrent hematologic malignancy. The
safety of this drug in healthy human volunteers [17], patients
withmyeloma and lymphoma for stem cell mobilization [18],
and patients with acute leukemia [15], has been established.
The most common adverse events attributable to plerixafor
in this study were mild and transient gastrointestinal effects
similar to that observed in other studies [15,17,18]. None of
our patients had an increase in blasts in the peripheral blood
after plerixafor. Symptomatic leukostasis was not observed
after plerixafor in adult patients with acute leukemia [15].
Prolonged cytopenias, a theoretical concern of the use of
CXCR4 antagonists with chemotherapy, were not observed in
our HSCT setting. Use of ﬂudarabine before plerixafor did not
result in neurotoxicity. The cardiac complications were sec-
ondary in origin and no patient had premature ventricular
contractions, as reported previously in 2 patients with a
history of cardiac disease [19].
Plerixafor exhibited linear pharmacokinetics in children,
andmost of the drug was eliminated within 24 to 48 hours of
administration. There are no published pharmacokinetic
parameters to compare with in either children or adults after
intravenous administration. After subcutaneous administra-
tion of .24 mg/kg of plerixafor in 13 adults with hematologicFigure 2. Clearance of plerixafor (L/hour/kg) with respect to the glomerular
ﬁltration rate (GFR; mL/min/1.73 m2).malignancies, the median AUC0-24, was 4299 (range, 2678 to
5287) hour  ng/mL, with a median terminal half-life of 4.6
(range, 2.7 to 11.7) hours [20]. This contrasts with a median
AUC0-24 of 1480 (range, 1477 to 3009) hour  ng/mL, with a
median terminal half-life of 2.19 (range, 1.68 to 3.07) hours,
after intravenous administration of .24 mg/kg in our study.
Subcutaneous concentration-time proﬁles, when compared
with intravenous proﬁles, after administration of .08 mg/kg
showed median peak concentration equivalent to 48%, fol-
lowed by identical AUC and elimination rates [17]. Hence, the
increased clearance in children cannot be attributed to the
route of administration alone. The relationship between
clearance of plerixafor and body weight shown in this study
supports dosing by body weight. Increased clearance in
males is a novel observation. There was no relationship be-
tween clearance and age after adjustment for body weight.
Clearance decreased after repeated administration of the
drug, with increase in the elimination half-life. The AUC in
dose level 2 was comparable to that achieved in adults after a
single dose administration. This supports using level 3 dosing
for children in future studies, both from safety and pharma-
cokinetic considerations. Plerixafor clearance was reduced in
the child with renal impairment and positively correlated
with GFR, as noted in adultswith renal impairment [21]. Dose
reduction in patients with mild renal impairment (60 to
89mL/minute/1.73m2)may result in exposure similar to that
in patients with normal renal function.
Previous studies have demonstrated an increase in CXCR4þ
blasts in the peripheral blood after plerixafor administration
[15]. Because serial marrow samples were not obtained
concurrently, it was unclear whether the change was due to
mobilization of CXCR4-expressing blasts from the marrow or
due to upregulation of CXCR4 surface expression. Herein, we
provide concurrent blood and marrow data for the ﬁrst time
and show that the percentage of CXCR4þ blasts increased
simultaneously in both compartments after plerixafor treat-
ment. Thus, thesedata argue against thenotion ofmigrationof
CXCR4þ blasts from the marrow to the blood; rather, they
support the hypothesis of upregulation of CXCR4 surface
expression. This hypothesis was further supported by our data
demonstrating an increase in CXCR4þ lymphocytes concur-
rentwith the increase inCXCR4þblasts in both compartments.
Mechanistically, the increase in surface expression may
be due to inhibition of Stromal derived factor-1aeinduced
internalization of CXCR4 [22], as hematopoietic cells are
known to contain large intracellular stores of CXCR4 [23].
Without concurrent chemotherapy, this phenotype of
increase circulating CXCR4þ blasts would be expected to
enhance leukemia dissemination; however when given with
conditioning chemotherapy, no increase in absolute number
of blasts was observed in the peripheral blood of our pa-
tients. The increase in CXCR4 expression in leukemia cells
and recipient lymphocytes during conditioningmay improve
leukemia control and reduce graft rejection, as augmented
CXCR4 signaling may induce apoptosis in AML cells via
regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak
[24]. Future studies may examine their in vitro susceptibility
to chemotherapeutic agents.
In this phase I study, where plerixafor was used in the
novel setting of a second allogeneic HSCT, we showed that it
was well tolerated, has unique pharmacokinetics in children,
and can pharmacodynamically increase CXCR4 expression on
leukemic blasts in the bone marrow and peripheral blood.
Engraftment was robust, even with a reduced-intensity
conditioning regimen. Despite a very poor expected
Figure 3. Percentages of CXCR4þ blasts (4A, 4B) and lymphocytes (4C, 4D) as detected by ﬂow cytometry (anti-CD184, clone ID9) in bone marrow (4A, 4C), and
peripheral blood (4B, 4D) before plerixafor (gray), and after plerixafor (black). Patient no. 3 did not have a satisfactory bone marrow sample for CXCR4 analysis.
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are alive; one half of them without evidence of disease.
Future studies using plerixafor in children with leukemia
undergoing a ﬁrst allogeneic HSCT are warranted.ACKNOWLEDGMENTS
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